Several stocks saw sharp declines or rebounds during the morning session as company-specific developments emerged, including Renascience's designation of RS5614 as an orphan drug and ZUU's discontinuation of its shareholder benefit program.
Renascience announced that RS5614, its investigational treatment for cutaneous angiosarcoma, had been designated as an orphan drug by the Minister of Health, Labour and Welfare. In a Phase II trial, the drug showed promising results when used in combination with paclitaxel, including a response rate of 13.3%, a disease control rate of 86.7%, median progression-free survival of 4.0 months and median overall survival of 20.8 months. The company is expected to hold discussions with the PMDA regarding the conduct of a Phase III trial. The designation is expected to make the drug eligible for preferential measures.
ZUU announced the discontinuation of its current shareholder benefit program, the “ZUU Premium Benefits Club.” Benefit points will end with 31 March 2026 as the record date, and no benefits will be provided based on 31 March 2027. Unused points may be exchanged for products during the applicable period, and the company will consider introducing a new shareholder benefit program.
Rentracks announced monthly sales for August of the fiscal year ending March 2027, reporting transaction volume of ¥5.786 billion and sales of ¥3.210 billion, both substantial increases. The results benefited from the consolidation, beginning with the fiscal year ending March 2027, of the results of 井嶋金銀工業, which became a subsidiary in February 2026.
Orchestra announced an expansion of its shareholder benefit program and an increase in its annual dividend, including expanded eligibility for shareholders holding at least 200 shares, an additional 10th-anniversary gift and an increase in the dividend from ¥30 to ¥50. The stock subsequently showed a buy indication at the daily price limit.
It has been reported that Nidec resolved to remove President Kishida (岸田) from office at an extraordinary meeting of the board held on 25 September. The company is also reportedly planning to record impairment losses on the scale of ¥1 trillion in response to accounting irregularities. The removal of the top executive while the company is rebuilding its management has heightened uncertainty.